Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13426 - 13450 of 15142 in total
ALMB-0168 is a humanized connexin 43 (Cx43) monoclonal antibody being investigated for osteosarcoma.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Withdrawn
A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific promoter (rAAVrh74.MHCK7.DYSF.DV).
Investigational
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
Matched Description: … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses …
Experimental
Withdrawn
Experimental
Withdrawn
Autologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.
Investigational
αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is...
Experimental
Matched Description: … inducer of Aβ,[A253203] which is the main component of the amyloid plaques found in individuals with AD and
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Displaying drugs 13426 - 13450 of 15142 in total